Regulus Therapeutics Inc. (NASDAQ:RGLS)

Join This Class Action

NEW YORK, NY and SAN DIEGO, CA – February 9, 2017 – Wolf Haldenstein Adler Freeman & Herz LLP  announces  that  a  class  action  lawsuit  has  been  filed  against  Regulus Therapeutics Inc. (“Regulus”  or the  “Company”) (NASDAQ:RGLS)  in the  United States District Court  for the Southern  District of California  on behalf  of persons or entities who purchased or otherwise acquired Regulus stock  between January 21, 2016 and June 27, 2016, inclusive (the “Class Period”).

Investors who have incurred losses in shares of Regulus Therapeutics Inc. are urged to contact the firm immediately at or (800) 575-0735 or (212) 545-4774. 

If   you have purchased  shares of Regulus Therapeutics Inc. within  the class period, you may, no later than April 3, 2017, request that the Court appoint you lead plaintiff of the proposed class.

The filed Complaint alleges that Defendants made false and/or misleading  statements and/or failed  to disclose  that: (1)  patients treated  with RG-101  were  at increased risk  of contracting  jaundice; (2)  consequently, the  Company  had overstated RG-101’s approval prospects and/or commercial viability; and (3) as a result of the foregoing,  Regulus’s public statements were materially  false and misleading at all relevant times.

On June 27,  2016, the Company  announced that it  had received verbal  notice from the U.S.  Food and Drug  Administration (“FDA”) that  the FDA had  placed RG-101 on clinical hold after a  second serious adverse event of jaundice  was reported in a  patient treated with  the drug.

On this news, the  Company’s share price fell $2.47, or more than 49%, to close at $2.54 on June 28, 2016.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at

## Follow the firm and learn about newly filed cases on Twitter and Facebook ##








Certification and Authorization Pursuant to Federal Securities Laws
  • The individual or entity listed below authorizes and, upon execution of the accompanying retainer agreement by Wolf Haldenstein Adler Freeman & Herz LLP, retains Wolf Haldenstein Adler Freeman & Herz LLP to file an action under the federal securities laws to recover damages and to seek other relief against Regulus Therapeutics Inc. (NASDAQ:RGLS). Wolf Haldenstein Adler Freeman & Herz LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses. The Regulus Therapeutics Inc. (NASDAQ:RGLS) Retention Agreement provided to the Plaintiff is incorporated by reference, upon execution by Wolf Haldenstein Adler Freeman & Herz LLP.

  • I, individually or on behalf of the entity I represent ("I"), hereby certify as follows:

    1. I have reviewed the complaint and authorize the filing of a lead plaintiff motion or action on my behalf.
    2. I did not acquire the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this private action or any other litigation under the federal securities laws.
    3. I am willing to serve as a representative party on behalf of a class, including providing testimony at deposition and trial, if necessary.
    4. I represent and warrant that I am fully authorized to enter into and execute this certification.
    5. I will not accept any payment for serving as a representative party on behalf of the class beyond my pro rata share of any recovery, except such reasonable costs and expenses (including lost wages) directly relating to the representation of the class as ordered or approved by the court.
    6. I have made no transaction(s) during the Class Period in the debt or equity securities that are the subject of this action except those set forth below:
  • Type of SecurityBuy Date (mm/dd/yy)# of SharesPrice per Share 
    Add a row
  • Type of SecuritySell Date (mm/dd/yy)# of SharesPrice per Share 
    Add a row
  • Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 03/29/2017